If in doubt perform a Diagnostic problems could evolve if a preg- culdocentesis order cytotec with a mastercard medicine park oklahoma. If an ultrasound machine is nant woman (confirmed by a positive UPT) present order 100mcg cytotec medicine allergy, assess for the presence of intrauterine shows no intrauterine pregnancy on vaginal ultra- pregnancy products and or blood in the sonography, has no fluid in Douglas’ pouch and pouch of Douglas. If still in doubt perform an has no signs of ectopic masses or gestational sacs. In this case she could have the following • Little tissue is obtained on performing an conditions: manual vacuum aspiration (MVA). In this • she could have had a complete miscarriage, case you might have mistaken an ectopic • she could have a pregnancy too early to be seen pregnancy for an incomplete abortion or you on ultrasound, might have left the gestational sac and its • she could have a spontaneously resolving intra- contents behind. One should always obtain uterine or tubal pregnancy, tissue when performing an MVA. This means In this case it may be appropriate to admit the that the patient has signs of hypovolemic patient and reassess her regularly in order not to shock which cannot be explained by the miss the ectopic pregnancy about to rupture. The monitor the patient’s vital signs on a daily basis. Only after 2 liters of take some time, depending on the gestational age) blood, or more, have been lost, a pregnant is it safe to discharge her. Ten to twenty per cent of clinically recognized • Always take proper patient history and perform pregnancies result in spontaneous miscarriage5. Miscarriage can speculum examination and a digital vaginal be a life-threatening condition when it results in examination. Abortions are unsafe when per- the loss of pregnancy below 24 weeks of gestation- formed by persons without the proper skills and al age. Moreover, the RCOG recommends the materials or outside a medically safe environment. The term miscar- By definition, miscarriage refers to the loss of a riage acknowledges the emotional aspects of losing pregnancy before the fetus has reached a viable ges- a pregnancy and prevents stigmatization of the tational age. Unfortunately, the cut-off point for a 8,9 pregnant woman and her medical caretaker. As a result of progressive medical knowledge carriage and abortion are presented in Table 2. This of emotional event for the woman and you should course heavily depends on the setting in which consider this while doing your consultation. In neonatal care can be provided and most likely does some cultures, stigmatization of the mother and/or not apply to your local setting. In short, the gesta- partner does occur, but pregnant women and their tional cut-off point for a loss of pregnancy to be partners are in fact not to be blamed. Fortunately, this lack of conformity in Etiology definition does not influence the general approach to diagnosis and treatment. In general, one can state The cause of spontaneous miscarriage is in most that the earlier a miscarriage occurs in pregnancy, cases related to the embryo itself. Table 2 Miscarriage: definitions of subcategories Spontaneous miscarriage Pregnancy loss within the first 24 weeks of gestation without deliberate interference Incomplete miscarriage Pregnancy loss within the first 24 weeks of gestation in which not all products of conception have been expelled at presentation Recurrent or habitual Three or more consecutive spontaneous abortions/miscarriages miscarriage Threatened miscarriage Uterine bleeding within the first 24 weeks of gestation without any cervical dilation. It is characterized by vaginal bleeding, lower back discomfort or midline pelvic cramping and a risk factor for miscarriage. This condition can be difficult to distinguish from ectopic pregnancy when no ultrasound is present Missed miscarriage Retention in the uterus of a dead embryo or fetus which has died within the first 16 weeks of gestation Induced abortion The intentional removal of a fetus from the uterus by any of a number of techniques Criminal abortion Illegal termination of pregnancy Legal abortion Termination of pregnancy under conditions allowed under local or national laws Therapeutic abortion or Abortion induced to save the life or health of a pregnant woman induced abortion for medical reasons Miscarriage with infection Any type of miscarriage, induced or spontaneous, that is associated with infection of the or infected abortion uterus and its appendages. It is characterized by fever, uterine tenderness, and foul discharge 26 Vaginal Bleeding in the First Trimester of Pregnancy Morphological abnormalities are most likely the Spontaneous miscarriage result of random chromosomal abnormalities (50– Signs are cramping, lower abdominal pain accom- 60%). Most commonly identified: Down’s syn- panied by clear, red vaginal bleeding. Sometimes drome, also called trisomy 21, polyploidy (more tissue and blood clots can be seen as well. Tissue is than one pair of chromosomes in the nucleus), 9 usually a dark purple color. To differentiate be- Turner’s syndrome or monosomy X. The fre- tween blood clots and (abortion) tissue you can put quency of spontaneous miscarriage increases with the clots/tissue in a glass container with normal tap maternal age. At the age of 35 years the incidence water and shake: blood clots will resolve, tissue will of spontaneous miscarriage reaches 20% and at the 10 stay intact. Up to 12 weeks the whole amniotic sac age of 40 it reaches 40–50%. Physical examination might maternal conditions can also lead to spontaneous show uterine enlargement. Digital vaginal exami- miscarriage: nation reveals an open ostium of the cervix, with • Diabetes, thyroid disease and infections, malaria, blood on the finger. In general, the bleeding dim- syphilis, gonorrhea, cytomegalovirus (CMV), inishes dramatically after complete evacuation of toxoplasmosis, listeria, HIV, parvo-B19, chlamy- the products of pregnancy. Some clots might be present • Genetic thrombophilias (clotting disorders) such in the fundus (top) of the uterus. Treatment If the amount of blood lost is less than • Acquired or congenital anatomical variations of generally perceived during normal menstruation or the uterus: septa, abnormalities of the uterine is dramatically diminishing, there is no need for cavity, myoma, adhesions of the uterine cavity, specific treatment. This means that a miscarriage has occurred but some products of conception are still present in the uterine cavity. The complaints are similar to those Epidemiology of spontaneous abortion, but in this case the vaginal bleeding has not stopped. Bleeding is usually more Spontaneous miscarriage is something which actu- than perceived during her normal menstrual period. Estimates are that one in On digital vaginal examination the ostium of the every eight pregnancies results in a spontaneous cervix is still open. Two out of ten women suffer from clots, parts of the amniotic sac or tissue in the uter- vaginal bleeding in the first trimester of pregnancy. Tissue appears as clear white In 50% of these cases the pregnancy is viable des- translucencies on the ultrasound, blood clots are pite the fact that bleeding continues. The other 11,12 less dense in nature, fluid or blood is dark. It is believed that many (more than 75%) pregnancies are lost be- Treatment This patient may need treatment with fore the woman recognizes she is actually pregnant. MVA or alternatively she can be treated with miso- The clinical signs of the miscarriage are in those prostol (see Chapter 13). If, during ultrasound ex- cases mistaken for delayed menstruation. As the amination, no embryo or fetus is seen and the tissue causes for miscarriage are so various, it is difficult to remaining in the uterine cavity has a diameter of say who will carry on and who not.
Because these studies did not report results separately for pioglitazone and rosiglitazone or they included only 1 of the thiazolidinediones discount 100 mcg cytotec free shipping medicine nobel prize, they do not provide information about the comparative safety of the thiazolidinediones order cytotec visa georges marvellous medicine. They do provide information about thiazolidinediones as a class compared with other antidiabetic agents. In 2 studies, thiazolidinediones were not associated with increased mortality compared 258, 261 with other oral hypoglycemic agents. In 1 study, pioglitazone was associated with reduced 243 all-cause mortality compared with other oral antidiabetic medications. In older patients with heart failure thiazolidinediones, either alone or combined with metformin, were associated with a lower risk of death over a 15-month period compared with patients not treated with an insulin 261 sensitizer. Two studies reported the incidence of coronary heart disease events (myocardial infarction or revascularization) with thiazolidinediones compared with metformin or sulfonylureas. A good-quality study using United States health insurance data found no increased risk of coronary heart disease events in patients initiating thiazolidinedione monotherapy 257 compared with those initiating metformin plus sulfonylurea combination therapy. The other found similar risks with rosiglitazone compared with sulfonylureas, metformin, or insulin, either 262 alone or in combination. Both studies also found no increased risk in the individual components of the composite outcome with thiazolidinedione use. Observational studies comparing adverse events associated with thiazolidinediones to adverse events associated with active controls Author, Year Data source, Sample Size Population (Quality) Comparison description Main outcomes Main results Adjusted odds ratio (95% CI) TZD vs. HR with propensity 243 2009 Rosiglitazone integrated All-cause adjustment, each compared to 19,717 vs. Lewis Nested case- Adjusted OR (95% CI) of any 263 2008 control; Kaiser adenoma on first colonoscopy, TZD vs. Hospital admission for congestive heart failure was the main outcome in a fair-quality 259 cohort study that used data from a Kaiser Permanente diabetes registry. Relative to patients initiating therapy with sulfonylureas, patients initiating therapy with thiazolidinediones were no more likely to experience a hospitalization for heart failure after an average of 10. A case-control study based on Oregon Medicaid claims data, in contrast, found a trend suggesting increased risk of hospitalization for heart failure associated with exposure to 265 thiazolidinediones within the previous 60 days. Increased risk was also found with exposure to insulin and to the combination of insulin plus thiazolidinediones, but not for other oral antidiabetic agents. A series of nested case-control studies found no difference in the incidence of breast, colon, or prostate cancer associated with exposure to thiazolidinediones compared with other 260 oral diabetic medications or insulin. A case-control study found a slightly higher odds of having an adenoma on first colonoscopy for subjects with type 2 diabetes exposed to TZDs 263 compared with those not exposed to TZDs. A study conducted in 500 primary care patients in Germany found fewer patients 256 progressed to insulin therapy when taking pioglitazone than when taking a sulfonylurea. However, because this study did not control for confounders and did not clearly report its recruitment strategy and other methods, these results may have a high risk of bias. The previous Drug Effectiveness Review Project TZDs report identified 43 additional 266-303 uncontrolled studies of adverse events associated with individual thiazolidinediones. The results of these studies were consistent with evidence from randomized controlled trials and comparative observational studies. Conclusions that can be drawn from this body of evidence are limited because the studies do not provide information about comparative harms. Fixed-dose Combination Products (FDCPs) or Dual Therapy Summary of findings for Fixed Dose Combination Products or Dual Therapy: Harms Harms in children • We did not find any evidence meeting inclusion/exclusion criteria for children. Harms in adults • We found no head-to-head trials that compared harms between any 2 FDCPs (insufficient strength of evidence). Rates of gastrointestinal adverse effects with Avandamet or dual therapy were high (28 to 47%), but were the same or slightly lower than those with metformin monotherapy (moderate strength of evidence). The 2 included trials were a 28 week trial (N=874) comparing 2 dosages of Avandaryl with glimepiride monotherapy and rosiglitazone monotherapy, and a 20 week trial (N=40) comparing concurrent use of rosiglitazone and glimepiride with rosiglitazone monotherapy. Evidence was limited to 1 trial (N=1,091, with outcomes reported at 24 and 54 weeks) including dual 31, 32 therapy with sitagliptin and metformin. Rates were slightly higher for sitagliptin 100 plus metformin 1000 compared with sitagliptin 100 monotherapy or with metformin 1000 monotherapy at 24 weeks (17. Detailed assessment for FDCPs and Dual Therapy: Harms We identified studies that have been conducted specifically using fixed-dose combination tablets 183, 185 comprised of rosiglitazone/metformin (Avandamet ), , rosiglitazone/glimepiride 186 139 (Avandaryl ), and pioglitazone/metformin (Actoplus Met ). Two of these were new since 139, 183 the 2007 Drug Effectiveness Review Project report on FDCPs. No studies were identified that used the fixed-dose combination tablets comprised of 189 190 pioglitazone/glimepiride (Duetact ) or sitagliptin/metformin (Janumet ). The safety of Duetact and Janumet have been established based on trials using the co-administration of their separate components. More detailed descriptions and summary tables for the studies in this section are provided in the corresponding section of Key Question 1 (Detailed assessment for FDCPs and Dual Therapy) related to efficacy. Details of included studies are found in Tables 37, 39, 41, and 43 and in Evidence Tables 5, 11. Throughout this section, meta-analyses were not performed due to an insufficient number of studies or heterogeneity of study populations, interventions, outcomes, and designs. No comparative cohort studies, case-control studies or systematic reviews were identified reporting harms. Table 66 summarizes adverse events of Avandamet (metformin + rosiglitazone) and rosiglitazone/metformin dual therapy in adults with type 2 diabetes. Head-to-head trials We found no head-to-head trials of Avandamet or dual therapy with metformin and rosiglitazone comparing them with other FDCPs that met inclusion criteria. Two trials compared Avandamet with metformin monotherapy; 1 of them also compared Avandamet with rosiglitazone monotherapy. The dual therapy trial compared concurrent use of metformin and rosiglitazone with metformin monotherapy. Mortality and withdrawals One death occurred in the dual therapy arm of 1 trial; no other deaths during or shortly after treatment were reported. Rates of withdrawal due to adverse events ranged from 1% to 7. In the Avandamet / dual therapy groups, rates of withdrawal due to adverse events were consistently slightly numerically lower than or equal to those in the monotherapy arms. Across trials, 1 rosiglitazone-treated patient and 2 dual therapy patients withdrew due to edema. One patient on metformin was withdrawn due to hypoglycemia. Gastrointestinal symptoms led 11 Avandamet and 7 metformin-treated patients to withdraw from studies. One metformin and 2 dual therapy patients withdrew due to cardiovascular events; 1 dual therapy patient experienced abnormal liver function values and withdrew. In the 2 Avandamet trials, rates of serious adverse events were equivalent between the Avandamet (3% to 4%) and monotherapy arms (3% to 4%). Other adverse events were mild to moderate in intensity. Hypoglycemia In both Avandamet trials, subjects on Avandamet reported slightly higher rates of hypoglycemia (7% to 12%) compared with metformin monotherapy (4% to 9%) or rosiglitazone monotherapy (8%).
Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving HAART generic 200 mcg cytotec with mastercard medicine upset stomach. Cytomegalovirus (CMV) blood DNA load buy 200mcg cytotec with mastercard symptoms 0f a mini stroke, CMV retinitis progression, and occurrence of resistant CMV in patients with CMV retinitis. Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: correlation of genotypic methods with viral phenotype and clinical outcome. Results of a cytomegalovirus (CMV)-specific CD8+/interferon-gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. Natural history and outcome of new AIDS-related cytomegalovirus retini- tis in the era of HAART. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV- infected patients receiving HAART. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and HAART in individuals infected with HIV-1. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-Naïve Patients with Advanced HIV-1 Infection in the HAART Era. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the ACTG. Cytomegalovirus polymerase chain reaction profiles in individuals with advanced HIV infection: relationship to CMV disease. Decrease of cytomegalovirus replication in HIV infected-patients after treatment with HAART. Cytomegalovirus IgG antibody is associated with subclinical carotid artery disease among HIV-infected women. Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. The search for new therapies for human cytomegalovirus infections. A role for CMV-specific CD4+CX3CR1+ T cells and CMV-induced T cell immunopathology in HIV-associated atherosclerosis. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy. Causes of visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in HIV-infected patients. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. Opportunistic Infections (OIs) 351 Candidiasis Candidiasis is an infection with yeast-forming fungi. Of the 150 Candida species known to date, only approximately 20 cause disease. Although it was commonly assumed that azole resistance is a problem particularly with albicans strains, this has not been the case to date (Sanglard 2002). Candidiasis is an important indicator of immunodeficiency and should be seen as a reason to consider starting ART, even with good immune status. Esophageal candidiasis and even oral thrush often occur following other OIs. Fever, not a classic symptom of candidiasis, is a particular indication to be on the alert for. If immune status is good, it must be remembered that there are also other reasons for thrush – alcoholism and steroid treatment are only two of many possibilities. In addition to candidiasis of the oropharynx and esophagus, vaginitis is a frequent problem in women (also occurring in healthy individuals). Candidemia occurs only rarely in HIV+ patients, even with severe immunodeficiency. Signs and symptoms The oropharynx is usually affected, with taste disturbances and sometimes a burning sensation on the tongue. White, non-adherent plaques on the buccal mucosa, tonsillar ring and tongue confirm the diagnosis. Occasionally, there may be atrophic candidiasis, which presents only with an erythematous mucosa. Candida esophagitis usually occurs with oropharyngeal involvement, but in about one third of cases there is no oral thrush. It often presents with dysphagia (“drink- ing is ok, but food can’t go down”) and retrosternal pain. Some patients complain of nausea, although vomiting occurs only rarely. Diagnosis Diagnosis in the oropharynx can be made based on clinical appearance. Characterization by culture or even determination of drug sus- ceptibility (beware laboratory uncertainty! Oral candidiasis is not to be confused with oral hairy leukoplakia (OHL). In contrast to candidiasis, the whitish, hairy plaques of OHL, on the sides of the tongue, cannot be scraped off. OHL is not caused by fungi but by EBV, and is an important disease marker for HIV, even if it is harm- less and does not require treatment. Candida esophagitis can also initially be diagnosed clinically. Dysphagia, retrosternal pain and oral candidiasis make the diagnosis very probable. Empiric fluconazole therapy reduces costs (Wilcox 1996). Upper GI endoscopy is only required if com- plaints persist.
They assessed growth by comparing mean height to height predicted at entry purchase generic cytotec line treatment 4 hiv. Changes in predicted mean heights after 12 and 24 months were not statistically significant buy cytotec 200mcg online treatment of diabetes. NCS Page 38 of 71 Final Report Update 1 Drug Effectiveness Review Project Table 14. Summary of growth outcomes Study Sample size Interventions Mean age (Total daily dose) % female Duration Outcome Results Beclomethasone aqueous Skoner, 2000 (336 mcg) compared with N=80 placebo Mean change in height 5. Are there subgroups of patients based on demographics (age, racial groups, gender), other medications, or comorbidities, or in pregnancy and lactation for which one nasal corticosteroid is more effective or associated with fewer adverse events? No studies stratified or analyzed data by subgroups of patients based on demographics, use of concomitant medications, or comorbidities. Race was only reported in one-third of all 14, 19, 23, 25-27, 54, 97, 103, 113 head-to-head trials and was predominantly Caucasian. Use of other concomitant nasal medications and/or presence of other concurrent nasal pathologies (e. Given NCS Page 39 of 71 Final Report Update 1 Drug Effectiveness Review Project these limitations, the demographic, concomitant medication usage, and comorbidity data provided can only be useful in determining the generalizability of results, but do not provide many insights into potential differences in efficacy or adverse events. Demographics Most head-to-head trials conducted in adults were comprised of comparable proportions of males (52%) and females (48%) and mean age overall was 33. One 4-week trial of mometasone 100 or 200 mcg and beclomethasone 400 mcg involved 477 adults with seasonal allergic rhinitis that were almost all 29 male (91. Indirect comparisons suggest that physician ratings of improvement and changes in total symptom scores were similar in this trial to other similar trials with higher proportions of female participants. In another trial of flunisolide 200 mcg compared with beclomethasone 400 mcg in adults with seasonal allergic rhinitis and a noticeably higher mean age of 66. It is not possible to draw conclusions about potential differential effects based on age using data from this trial, as the lower rates could also have been due to the use of a more stringent definition of improvement (total compared with significant). With regard to race, 1 study compared the adverse sensory attributes of fluticasone, mometasone, and triamcinolone in 364 adults with perennial allergic rhinitis who were all of 101 Asian descent. It is not possible to compare treatment effects in this trial to those reported in other similar head-to-head trials due to heterogeneity in outcome reporting. The only other evidence of safety and efficacy in an elderly population (65-87 years) with perennial allergic rhinitis was found in an unpublished 12-week placebo-controlled trial of mometasone identified in our dossier review. Mometasone 200 mcg/day was found to be significantly more effective than placebo in reducing total nasal symptom scores in the first 2 weeks. Local adverse effects such as headache, pharyngitis, coughing, and epistaxis occurred more frequently in the 125 mometasone treatment group although statistical significance was not reported. Trials in children were comprised of more males (65%) than females and the mean age overall was 9 years. Similarly, trials of adolescents were comprised of mostly males (90%) and 38, 85, 88 the mean age was 14 years. The highest reported prevalence of male participants (97%) was reported in 1 of the trials of adolescents with seasonal allergic rhinitis that compared 2 38 weeks of treatment with fluticasone 100 or 200 mcg with placebo (N=243). Rates of patients with significant improvement in this trial appear similar to those in other placebo-controlled trials of fluticasone and this evidence does not suggest that fluticasone has differential effects based on gender. The only evidence of using nasal corticosteroids in very young children comes from placebo-controlled trials of fluticasone or mometasone. The first 6-week study found fluticasone safe and effective for 26 very young children between ages of 2 and 4 years with confirmed 126 perennial rhinitis. This randomized double-blind double-dummy placebo-controlled trial compared fluticasone 100 mcg and an oral placebo with ketotifen 1 mg (an antihistamine with mast-cell stabilizer activity) and a placebo nasal spray. The fluticasone treatment group showed statistically better efficacy for total nighttime and daytime symptom scores and for nasal blockage at 4-6 weeks. All other individual symptom scores revealed no significant differences between treatment groups. As a secondary outcome, investigators assessed 9 children using fluticasone to have experienced improvement or substantial improvement, while only 4 in the NCS Page 40 of 71 Final Report Update 1 Drug Effectiveness Review Project ketotifen group had the same level of improvement. There were as well no significant differences in frequency of adverse events. Additional evidence of safety in young children between the ages 2-5 years comes from an unpublished placebo-controlled trial of mometasone that was revealed in our dossier review. There were no serious adverse events found during the 6-week treatment period and headache and rhinorrhea were more common in the placebo group, while upper respiratory tract infection and skin trauma occurred more frequently in children using 125 mometasone. Withregardtorace,1placebo-controlledtrial examined the potential growth suppression 114 effects of beclomethasone AQ 336 mcg over 1 year in 80 children that were 57% black. This data is only descriptive, however, and does not provide evidence of the comparative effects of beclomethasone relative to other nasal corticosteroids based on race. Asthma 13, 16, 20, 21, Patients with comorbid asthma were included in 8 head-to-head trials in adults. Only 1 trial conducted any subgroup analyses of the patients with comorbid 13 asthma, but the focus was only on asthma symptom outcomes. This subgroup analysis involved patients with fall seasonal asthma and was conducted on 19 patients using flunisolide and 11 13 patients using beclomethasone nasal sprays. The authors reported that baseline scores for chest symptoms were similar for both groups. During the peak of ragweed season the placebo-treated patients reported a 10-fold increase in symptoms compared to patients treated with nasal corticosteroids. The expected symptoms of asthma did not occur in most of the active treatment patients. The study was not designed for rigorous evaluation of asthma symptoms and patients were not screened with pulmonary function tests, nor was the asthma monitored throughout the trial with peak flow meters or spirometry. One small (N=28), fair quality, randomized, placebo-controlled, double-blind crossover trial examining intranasal beclomethasone aqueous in pediatric patients (mean age 10 years) with perennial allergic rhinitis and concomitant asthma showed positive effects on rhinitis symptoms 127 and mixed effects on asthma symptoms. After 4 weeks, the mean rhinitis symptom scores were lower for those taking beclomethasone in the morning (P=0. In contrast, the morning asthma symptom scores were lower for beclomethasone at end of the study (P=0. Results showed that nasal medication controlled nasal symptoms and inhaled medication controlled pulmonary symptoms but did not reduce reported symptoms in the untreated disease. The combined treatment did well in alleviating overall pollen-induced symptoms. Another smaller 16-week active control study (N=59) looked at cross symptoms in patients with allergic rhinitis and mild-to-moderate asthma in 3 groups: nasal beclomethasone, 129 inhaled beclomethasone, and combined treatment. Results showed that self-assessed asthma symptom scores (from patient diaries) do improve significantly when treated with nasal NCS Page 41 of 71 Final Report Update 1 Drug Effectiveness Review Project beclomethasone only (P=0.